UNH Stock: UnitedHealth Group Incorporated — Profile, Analysis & Investor Guide (2026)
The world’s largest healthcare company by revenue, providing insurance and data-driven health services — Updated June 2026 with current price, P/E ratio, analyst ratings, financials, and investor insights.
UnitedHealth Group Incorporated (UNH) stands as a diversified healthcare powerhouse, operating through two primary platforms: UnitedHealthcare for health benefits and Optum for health services. As a bellwether for the managed care industry, UNH provides a comprehensive suite of products ranging from employer-sponsored insurance to Medicare and Medicaid plans. While some investors seek high-risk volatility in Micro Cap Oil Stocks, UnitedHealth offers a more defensive posture backed by massive scale and predictable cash flows.
The company’s strategic focus on integrating clinical care with advanced data analytics through its Optum division has created a formidable competitive moat. This “flywheel” effect allows UnitedHealth to manage medical costs more effectively than smaller peers. When compared to the relatively small market footprints of companies found in the List Of Publicly Traded Sports Franchises, UNH represents a massive pillar of the U.S. economy, consistently ranking among the top firms in the Fortune 500. For investors navigating the current market, UNH serves as a core holding that balances growth in its health services sector with the stability of its insurance premiums.
Key Takeaways — UNH Stock
UnitedHealth is the undisputed leader in health insurance and pharmacy benefit management, serving over 150 million individuals worldwide.
The Optum segment (Health, Insight, and Rx) continues to outpace the core insurance business, providing higher-margin technology and clinical services.
With a 2.25% yield and a strong track record of annual increases, UNH is a favorite for dividend growth investors looking for defensive income.
Analysts maintain a Strong Buy rating with a target of $417.00, citing the company’s ability to navigate regulatory shifts and maintain 12%+ EPS growth.
UNH Stock Health Score
Scores out of 10 based on current fundamentals, valuation, momentum and income data.
UNH — Live Stock Chart
Real-time price chart powered by TradingView.
UNH — Key Statistics & Valuation
Core financial data as of June 2026.
| Valuation | Value | Financials | Value |
|---|---|---|---|
| Market Cap | $369.32B | Revenue (TTM) | $449.71B |
| P/E Ratio (TTM) | 30.77 | Net Income | $12.04 billion |
| Forward P/E | 22.48 | EPS (TTM) | $13.24 |
| Price/Sales | 0.82 | Gross Margin | 18.2% |
| Price/Book | 4.55 | Net Margin | 2.68% |
| PEG Ratio | 2.14 | ROE | 12.31% |
| Beta | 0.64 | Debt/Equity | 0.72 |
| 52-Week High | $415.98 | 52-Week Low | $234.60 |
| Avg Daily Volume | 8.21 million | YTD Return | 21.95% |
| 1-Year Return | 38.84% | 5-Year Return | 7.28% |
| Dividend Yield | 2.25% | Payout Ratio | 48.2% |
| Analyst Rating | Strong Buy | Price Target | $417.00 |
| Sector | Healthcare | Industry | Healthcare Plans |
| CEO | Stephen J. Hemsley | Employees | 390,000 |
| Founded | January 1977 | Headquarters | Eden Prairie, Minnesota, US |
UNH — Business Overview
UnitedHealth provides medical benefit plans for individuals and employers, alongside health services through Optum, which includes pharmacy care, clinics, and data analytics.
Revenue is primarily generated through monthly insurance premiums and service fees from healthcare providers and organizations using Optum’s technology and pharmacy platforms.
Their massive scale provides unparalleled bargaining power with hospitals, while their vertical integration (insurance + care delivery) allows for superior cost control.
The aging U.S. population is driving massive enrollment in Medicare Advantage, a segment where UnitedHealth holds a leading market share.
UNH — Financial Performance Snapshot
| 📈 Growth | Value | 📊 Profitability | Value | 🎯 Valuation | Value |
|---|---|---|---|---|---|
| Revenue Growth YoY | 14.2% | Gross Margin | 18.2% | P/E Ratio | 30.77 |
| EPS Growth YoY | 11.8% | Net Margin | 2.68% | Forward P/E | 22.48 |
| 5Y Revenue CAGR | 10.5% | ROE | 12.31% | PEG Ratio | 2.14 |
| Free Cash Flow | $18.4B | Operating Margin | 7.9% | Price/Sales | 0.82 |
UNH — Analyst Ratings & Price Target
Based on 28 analysts covering UNH as of June 2026.
High: $460.00 | Low: $385.00 | Upside from current: 0.85%
24 Buy | 3 Hold | 1 Sell ratings from covering analysts.
Goldman Sachs maintained a Buy rating, citing strong medical loss ratio management in the latest quarter.
UNH Technical Analysis
Real-time buy/sell signals from TradingView.
UNH — Pros & Cons
✓ Diversified Revenue
Unlike pure-play insurers, UNH gets significant earnings from its Optum health services division, reducing reliance on insurance premiums.
✗ Regulatory Pressure
The healthcare sector is a frequent target for political debate, with potential changes to Medicare rates or drug pricing hitting margins.
✓ Strong Cash Flow
The company generates massive free cash flow, allowing for consistent dividend hikes and aggressive share buybacks.
✗ Medical Loss Ratio Volatility
Unexpected spikes in medical utilization (like a severe flu season or pandemic resurgence) can suddenly increase costs for the insurance arm.
✓ Low Beta Stability
With a beta of 0.64, the stock is significantly less volatile than the broader market, making it an excellent defensive holding.
✗ High P/E Relative to Peers
A P/E of 30.77 is higher than many direct competitors, meaning the market has already priced in significant future growth.
Who Should Consider UNH?
Conservative investors looking for steady dividend growth and a defensive “Blue Chip” anchor for their portfolio.
Short-term speculators or those seeking explosive 10x returns often found in the Small Cap Aerospace & Defense Stocks sector.
Long-term (3-5+ years) to fully benefit from the compounding effects of dividend reinvestment and demographic tailwinds.
A tax-advantaged account like an IRA is ideal to shield the quarterly dividend payments from immediate taxation.
UNH vs Competitors
| Company | Ticker | Market Cap | P/E | Rev Growth | Net Margin | Dividend | 1Y Return |
|---|---|---|---|---|---|---|---|
| UnitedHealth Group ★ | UNH | $369.32B | 30.77 | 14.2% | 2.68% | 2.25% | 38.84% |
| CVS Health | CVS | $72.4B | 11.2 | 8.5% | 2.1% | 3.8% | -5.2% |
| Elevance Health | ELV | $121.6B | 18.5 | 7.2% | 3.5% | 1.4% | 12.4% |
| The Cigna Group | CI | $98.2B | 14.8 | 9.1% | 2.9% | 1.6% | 18.1% |
UNH — Key Risks
Medicare Funding Cuts
Potential reductions in government reimbursement rates for Medicare Advantage could significantly compress UnitedHealth’s core profit margins.
Antitrust Scrutiny
The company’s massive size and vertical integration have drawn attention from regulators concerned about fair competition in the health services market.
Data Breaches
As a massive aggregator of health data, UNH is a prime target for cyberattacks, which can lead to immense legal liabilities and reputational damage.
Drug Pricing Reform
Legislative changes affecting how pharmacy benefit managers (PBMs) operate could disrupt the revenue model of the OptumRx division.